CN102008491A - Fosinopril-containing compound preparation for treating hypertension - Google Patents
Fosinopril-containing compound preparation for treating hypertension Download PDFInfo
- Publication number
- CN102008491A CN102008491A CN 201010231054 CN201010231054A CN102008491A CN 102008491 A CN102008491 A CN 102008491A CN 201010231054 CN201010231054 CN 201010231054 CN 201010231054 A CN201010231054 A CN 201010231054A CN 102008491 A CN102008491 A CN 102008491A
- Authority
- CN
- China
- Prior art keywords
- fosinopril
- compound preparation
- levamlodipine
- pharmaceutically acceptable
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a fosinopril-containing compound preparation for treating hypertension, which comprises the main components of L-amlodipine or pharmaceutically acceptable salt thereof, hydrochlorothiazide and fosinopril or pharmaceutically acceptable salt thereof, and the auxiliary component of a pharmaceutically acceptable carrier, wherein the content of the L-amlodipine or the pharmaceutically acceptable salt thereof in unit preparation is 2.5-10.0mg. The invention has the advantages of fully exerting medicine compensation action mechanism through medicine combination therapy, increasing curative effect, quickly reaching the standards, making the compliance rate of blood pressure reach 82%, reducing adverse effect associated with the dose increase of certain medicine and keeping longer action time. The compound preparation has the characteristics of quick effect taking, high compliance rate of blood pressure, little side effect and low cost.
Description
Technical field:
The present invention relates to a kind of compound preparation that hypertension contains fosinopril for the treatment of, belong to drug world.
Background technology:
Along with China's rapid growth of economy, the drastic change of people life style, the acceleration of urbanization, aging, the cardiovascular diseases has become first or second cause of the death of rural and urban population.Especially patients with hypertension, its sickness rate accounts for total population about 15%.Morbidity colony is so big, seeks medicine evident in efficacy, that side effect is little and seems more important.
The hypertensive medicine of treatment has multiple at present, such as calcium antagonist (CCBs), converting enzyme inhibitor (ACEI), Angiotensin (ARBs) etc., but single medicine treatment hypertension is difficult up to standard in a short time, and Most patients need be taken two or more antihypertensive drug can reach the blood pressure lowering target.Especially blood pressure exceeds desired value 20/10mmHg, and beginning need be taken two kinds of medicines often.Single medicine is prone to drug resistance, and because the bigger probability that toxicity occurs of dosage is also bigger.Majority is to give two or more drug administration treatments simultaneously.But several drugs is taken simultaneously, and patient's compliance is poor, and the collocation of the dosage of several drugs is not because the problem of formulation dosage and doctor's the degree of awareness often are optimized proportionings.In recent years, though the depressor of much new good effect few side effects is arranged, the controlling blood pressure compliance rate is relatively low.But drug combination can be used two or more depressor, and the dosage of every kind of medicine is little, and the therapeutical effect of medicine should have collaborative or the effect of addition at least, and its ill effect can be cancelled out each other or not overlapping at least or addition.Medicine kind number used during drug combination is too much unsuitable, and crossing to have complicated drug interaction at most.Therefore, select to merge very difficulty of medication amount and kind, need a large amount of development tests.
Therefore, a kind of new treatment pattern is applied to clinical gradually, and the compound hypertension medicine preparation is internationally recognized a kind of orientation treatment.Because the compound antihypertensive drug prescription is followed the principle that different mechanism of action medicines carry out proportioning usually, therefore show as the advantage that increases curative effect or reduce side effect, obtained better controlling of blood pressure effect.
Summary of the invention:
The object of the present invention is to provide a kind of side effect little, taking convenience can effectively be treated the compound preparation of three kinds of antihypertensive drugs of hypertensive combination, and this compound preparation is controlling blood pressure effectively.
Purpose of the present invention is implemented by following technical scheme: a kind ofly treat the compound preparation that hypertension contains fosinopril, it includes following composition: Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, hydrochlorothiazide (hydrochlorothiazide), fosinopril (fosinopril) or its officinal salt are Main Ingredients and Appearance, being equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described fosinopril (fosinopril) or its officinal salt, count 5.0-40.0mg with fosinopril, described hydrochlorothiazide (hydrochlorothiazide) is 6.25-25.0mg.
It is a kind of that to treat the compound preparation that hypertension contains fosinopril be capsule, soft capsule, granule, tablet, powder, slow releasing agent or injection dosage form.
Advantage of the present invention: be to give full play to the complementary mechanism of action of medicine according to drug combination to increase curative effect, up to standard fast, make the blood pressure compliance rate reach 82%, reduce with a certain dosage and increase relevant untoward reaction.Compound formulation of the present invention has instant effect, blood pressure compliance rate height, and side effect is little, the characteristics that cost is low.
The specific embodiment:
Further set forth medicine of the present invention by the following examples, these embodiment are only presented for purposes of illustration, do not limit the scope of the invention.
Embodiment 1-4 is listed as follows:
Use the conventional method in the pharmaceuticals industry among the embodiment, the according to the form below formulation becomes tablet, makes the used pharmaceutically suitable carrier of tablet--and adjuvant is the conventional adjuvant of this area.Wherein the proportioning of its Main Ingredients and Appearance is as follows:
| Embodiment | Count (mg/ sheet) with Levamlodipine | Count (mg/ sheet) with fosinopril | Hydrochlorothiazide (mg/ sheet) |
| 1 | Levamlodipine 2.5 | Fosinopril 5.0 | Hydrochlorothiazide 6.25 |
| 2 | Levamlodipine 2.5 | Fosinopril 40.0 | Hydrochlorothiazide 12.5 |
| 3 | Levamlodipine 5.0 | Fosinopril 10.0 | Hydrochlorothiazide 25.0 |
| 4 | Levamlodipine 10.0 | Fosinopril 20.0 | Hydrochlorothiazide 12.5 |
Use the conventional method in the pharmaceuticals industry simultaneously among the embodiment, can also be prepared into capsule, soft capsule, granule, powder, controlled release agent or injection dosage form,, pharmaceutically suitable carrier--used adjuvant is the conventional adjuvant of this area of this dosage form.
Embodiment 5: the present invention treats hypertensive compound preparation clinical trial:
To illustrate that pharmaceutical composition of the present invention is to hypertensive therapeutical effect by the human body pharmacodynamic experiment below.
1, physical data:
Clinical 400 routine hypertension philtrums, age 40--50 year, 150 examples; Age 51--60 year, 150 examples, age 61--70 year, 100 examples.
2, diagnostic criteria: according to " Chinese hypertension prevention and control guide ", hypertension is defined as: do not obey under the antihypertensive situation systolic pressure 〉=140mmHg and/or diastolic pressure 〉=90mmHg.
3, Therapeutic Method:, adopt randomized to be divided into 4 groups, every group of this compound formulation medicine that adopts embodiment of the invention 1-4 gained respectively with 400 routine hypertensive patients, make tablet, every day is once oral, according to the dose difference of tablet, each a slice or two took 6 days.
4, efficacy assessment standard:
Draft according to " Chinese hypertension prevention and control guide ".The target of antihypertensive therapy is blood pressure to be returned to " normally " or " ideal " level.40-60 year patient be depressurized to ideal or normal arterial pressure (≤130/85mmHg), 60-70 year patient be depressurized at least normal high value (≤140/90mmHg).
5, therapeutic outcome: administration begins to carry out respectively in the 1st day, 2 days, 3 days, 4 days, 5 days, 6 days blood pressure determination.The result shows that medication is after 6 days, 4 groups of the embodiment of the invention are totally 400 routine hypertension philtrums, and it is up to standard to amount to 330 routine patient's blood pressures, promptly returns to " normally " or " ideal " level, mean blood pressure compliance rate 82% illustrates that the present embodiment compound medicine has good curing hypertension effect.
Curative effect sees the following form:
| Case load | Blood pressure case sum up to standard | The below standard case sum of blood pressure | The mean blood pressure compliance rate |
| 400 | 330 | 70 | 82％ |
Discuss
This product is the compound formulation that brings high blood pressure down, and is applicable to treatment hypertension, and its blood pressure compliance rate is higher.
Claims (2)
1. treat the compound preparation that hypertension contains fosinopril for one kind, it is characterized in that, it includes following composition: Levamlodipine or Levamlodipine officinal salt, hydrochlorothiazide, fosinopril or its officinal salt be Main Ingredients and Appearance, be equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described fosinopril or its officinal salt, count 5.0-40.0mg with fosinopril, described hydrochlorothiazide is 6.25-25.0mg.
2. according to the described a kind of compound preparation that hypertension contains fosinopril for the treatment of of claim 1, it is characterized in that described compound preparation is capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010231054 CN102008491A (en) | 2009-07-14 | 2010-07-08 | Fosinopril-containing compound preparation for treating hypertension |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910139997 | 2009-07-14 | ||
| CN200910139997.8 | 2009-07-14 | ||
| CN 201010231054 CN102008491A (en) | 2009-07-14 | 2010-07-08 | Fosinopril-containing compound preparation for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102008491A true CN102008491A (en) | 2011-04-13 |
Family
ID=43709405
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010230017 Pending CN101985035A (en) | 2009-07-14 | 2010-07-08 | Perindopril-containing compound preparation for treating hypertension |
| CN 201010231054 Pending CN102008491A (en) | 2009-07-14 | 2010-07-08 | Fosinopril-containing compound preparation for treating hypertension |
| CN 201010231091 Active CN102008712B (en) | 2009-07-14 | 2010-07-08 | Trandolapril-containing compound preparation for curing hypertension |
| CN 201010231061 Active CN102008708B (en) | 2009-07-14 | 2010-07-08 | Ramipril-contained compound preparation for treating hypertension |
| CN 201010231039 Active CN102008707B (en) | 2009-07-14 | 2010-07-08 | Quinapril-contained compound preparation for treating hypertension |
| CN 201010230019 Pending CN101984972A (en) | 2009-07-14 | 2010-07-08 | Benazepril-containing compound preparation for treating high blood pressure |
| CN 201010231077 Active CN102008710B (en) | 2009-07-14 | 2010-07-08 | Lisinopril-containing compound preparation for treating hypertension |
| CN 201010231082 Active CN102008711B (en) | 2009-07-14 | 2010-07-08 | Compound preparation containing enalapril for treating hypertension |
| CN 201010231068 Active CN102008709B (en) | 2009-07-14 | 2010-07-08 | Moexipril-contained compound preparation for treating hypertension |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010230017 Pending CN101985035A (en) | 2009-07-14 | 2010-07-08 | Perindopril-containing compound preparation for treating hypertension |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231091 Active CN102008712B (en) | 2009-07-14 | 2010-07-08 | Trandolapril-containing compound preparation for curing hypertension |
| CN 201010231061 Active CN102008708B (en) | 2009-07-14 | 2010-07-08 | Ramipril-contained compound preparation for treating hypertension |
| CN 201010231039 Active CN102008707B (en) | 2009-07-14 | 2010-07-08 | Quinapril-contained compound preparation for treating hypertension |
| CN 201010230019 Pending CN101984972A (en) | 2009-07-14 | 2010-07-08 | Benazepril-containing compound preparation for treating high blood pressure |
| CN 201010231077 Active CN102008710B (en) | 2009-07-14 | 2010-07-08 | Lisinopril-containing compound preparation for treating hypertension |
| CN 201010231082 Active CN102008711B (en) | 2009-07-14 | 2010-07-08 | Compound preparation containing enalapril for treating hypertension |
| CN 201010231068 Active CN102008709B (en) | 2009-07-14 | 2010-07-08 | Moexipril-contained compound preparation for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (9) | CN101985035A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319252A (en) * | 2011-07-22 | 2012-01-18 | 海南锦瑞制药股份有限公司 | Amlodipine and fosinopril sodium medical composition and preparation method thereof |
| CN102342948A (en) * | 2011-07-14 | 2012-02-08 | 海南锦瑞制药股份有限公司 | New oral solid medicinal composition and preparation method thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423482B (en) * | 2011-11-17 | 2013-09-25 | 南京瑞尔医药有限公司 | preparation method of compound amlodipine-lisinopril tablets |
| CN102423483A (en) * | 2011-11-24 | 2012-04-25 | 西北农林科技大学 | Compound ramipril nano-emulsion for antihypertension |
| CN107029208A (en) * | 2017-06-13 | 2017-08-11 | 江苏黄河药业股份有限公司 | It is a kind of to treat lisinopril compound preparation of angiocardiopathy and preparation method thereof |
| CN110755397A (en) * | 2018-07-26 | 2020-02-07 | 北京市石景山区高血压联盟研究所 | Compound antihypertensive drug tablet and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137367A (en) * | 2003-10-20 | 2008-03-05 | 诺瓦提斯公司 | Benazapril and amlodipine besylate for reducing cardiovascular morbidity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1237966C (en) * | 2003-09-12 | 2006-01-25 | 启东盖天力药业有限公司 | Compound preparation for lowering the blood pressure |
-
2010
- 2010-07-08 CN CN 201010230017 patent/CN101985035A/en active Pending
- 2010-07-08 CN CN 201010231054 patent/CN102008491A/en active Pending
- 2010-07-08 CN CN 201010231091 patent/CN102008712B/en active Active
- 2010-07-08 CN CN 201010231061 patent/CN102008708B/en active Active
- 2010-07-08 CN CN 201010231039 patent/CN102008707B/en active Active
- 2010-07-08 CN CN 201010230019 patent/CN101984972A/en active Pending
- 2010-07-08 CN CN 201010231077 patent/CN102008710B/en active Active
- 2010-07-08 CN CN 201010231082 patent/CN102008711B/en active Active
- 2010-07-08 CN CN 201010231068 patent/CN102008709B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137367A (en) * | 2003-10-20 | 2008-03-05 | 诺瓦提斯公司 | Benazapril and amlodipine besylate for reducing cardiovascular morbidity |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342948A (en) * | 2011-07-14 | 2012-02-08 | 海南锦瑞制药股份有限公司 | New oral solid medicinal composition and preparation method thereof |
| CN102319252A (en) * | 2011-07-22 | 2012-01-18 | 海南锦瑞制药股份有限公司 | Amlodipine and fosinopril sodium medical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008708B (en) | 2013-02-20 |
| CN102008709A (en) | 2011-04-13 |
| CN102008710B (en) | 2013-02-20 |
| CN101985035A (en) | 2011-03-16 |
| CN102008710A (en) | 2011-04-13 |
| CN102008712A (en) | 2011-04-13 |
| CN102008711B (en) | 2012-12-26 |
| CN101984972A (en) | 2011-03-16 |
| CN102008707B (en) | 2012-12-26 |
| CN102008712B (en) | 2012-12-26 |
| CN102008711A (en) | 2011-04-13 |
| CN102008707A (en) | 2011-04-13 |
| CN102008708A (en) | 2011-04-13 |
| CN102008709B (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008483A (en) | Candesartan-containing compound preparation for treating hypertension | |
| CN102008710B (en) | Lisinopril-containing compound preparation for treating hypertension | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| CN101966189A (en) | Amlodipine and olmesartan-containing compound preparation for treating hypertension | |
| CN101371834B (en) | Medicament composition containing amlodipine besylate and candesartan cilexetil and medicine box | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| CN101954082A (en) | Angiotensin-converting enzyme inhibitor-containing compound preparation for treating hypertension | |
| CN110325214A (en) | Low-dose drugs for preventing and treating neure damage combine | |
| CN113648380A (en) | Composition for treating diabetes | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN1299676C (en) | Anti-anoxia medicinal composition | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN113616651B (en) | Compound antihypertensive pharmaceutical composition and application thereof | |
| CN101596203B (en) | Application of syringin in preparing drugs for treating cardiovascular and cerebrovascular diseases | |
| CN101125144A (en) | Compound medicine for treating diabetes | |
| CN117243947A (en) | Application of daphnetin and combination containing daphnetin in preparation of diabetes complication medicaments | |
| CN105213398B (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN102743361A (en) | Irbesartan hydrochlorothiazide capsule | |
| CN107648226A (en) | A kind of pharmaceutical composition for treating antimigraine and preparation method thereof | |
| CN107648225A (en) | A kind of antihypertensive Western medicine compound and preparation method thereof | |
| CN101623294B (en) | Composition for reducing blood pressure | |
| CN107648239A (en) | A kind of Western medicine compound for treating hypertension and preparation method thereof | |
| CN101518536A (en) | Ease blood pressure reducing capsule | |
| CN101756973A (en) | Compound antihypertensive preparation | |
| CN102552277A (en) | Amlodipine, aliskiren and hydrochlorothiazide compound antihypertensive medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110413 |